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ABSTRACT
Asthma treatments have changed radically due to
elucidation of morbidity and development of medi-
cine/treatment strategies. The Global Initiative for
Asthma consists of a six-part asthma management
program and seven defined states for controlled
asthma worldwide. However, considering the present
status of asthma in infants through to young adult
patients, it is extremely difficult to implement these ideal
programs and to attain their goals. At the Pediatric Unit
in the National Minami Fukuoka Chest Hospital, the
number of out-patients and patients hospitalized due to
asthma attacks increased continuously from 1975 until
1987 at respective rates of 4.9-fold (from 466 to 2295
patients) and 10.6-fold (from 118 to 1245 cases).
Thereafter, the number of out-patients has remained
stable (1999 patients in 1997), while the number of
hospitalizations has decreased (766 in 1997). How-
ever, the age-specific distribution of hospitalized
patients has changed remarkably. There are two peaks:
one in the infant population and another in older ele-
mentary school students. In the past, the incidence of
hospitalization was higher among older elementary
school students, although now the situation has been
reversed, with as many as 53.6% (323 patients) of
patients aged between 0 and 3 years of age being hos-
pitalized in 1999 and more patients being identified
with complications. This reversal could be largely attrib-
utable to the fact that whereas strong medications 
and therapies, such as round the clock therapy with
theophylline, disodium cromoglycate inhalation and
inhalation of steroids, have become standard treat-
ments for older elementary school children with
asthma, these therapies, especially steroid inhalation,
may be difficult to use for the treatment of infants and,
therefore, pediatricians are hesitant to use these treat-
ment strategies. The elevated incidence rate of asthma
and its higher incidence in younger children may also
be an underlying cause. In contrast, asthma mortality at
our pediatric unit has never increased, on average one
patient yearly, and most of these cases were deaths at
home or deaths on the way to hospital. With regard to
asthma death statistics in Japan, a sudden increase in
deaths due to asthma was noted among children aged
10–14 years in the 1960s, whereas no such increase in
deaths due to asthma has been noted since the 1970s.
This suggests a big step ahead in terms of the treatment
and management of children with bronchial asthma.
However, the long-term prognosis of severe childhood
refractory asthma is not good. In our prognosis study
on severe asthma patients who were hospitalized 20
years ago, 27.2% experienced remission and 12.7%
died, and residual impaired pulmonary function was
noted in many cases. Among the 24 cases of death, we
have been notified that 20 cases of sudden death were
patients aged between 10 and 29 years of age. The
mortality rate in patients aged 15–29 years in Japan
increased threefold during the subsequent 10 years
from 1980. Although this rate has apparently started
to decrease in the past 5 years, compared with the
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estimated bronchial asthma incidence rate from the
International Study of Asthma and Allergies in Child-
hood (ISAAC) study, the bronchial asthma mortality rate
in Japan is definitely higher than in Western countries.
These data suggest difficulty in the management of
adolescent and young adult patients with severe
asthma, who often have a psychological/social/eco-
nomic handicap. The relatively high asthma mortality
rate in Japan may be attributable to: (i) a greater
number of patients with severe asthma; (ii) the poor
medical supply system; (iii) a lack of asthma education
for both physicians and patients; and (iv) problematic
treatment regimens. In present paper, the first point is
discussed in relation to the ISAAC study, the second
point is discussed with regard to the system for out-
patients’ overnight visits, the third point is discussed
with regard to the educational/cooperative system
involving school and society, and the fourth point is dis-
cussed in terms of treatments with steroids inhalation
and β-adrenergic receptor agonsists. In conclusion, the
overall control of bronchial asthma can certainly be
achieved more easily now, as seen by the reduction in
the number of hospitalizations from asthma attacks
and the year-round number of patients with severe
asthma. However, infant asthma patients do not show
this tendency and this requires investigation into treat-
ment regimens involving morbidity analysis and early
interventions. In addition, severe childhood refractory
asthma presents various current and future problems.
In fact, these patients are facing many problems, such
as long-term use of multiple medications, disturbances
to everyday life, obstacles to higher education/work, an
inadequate system of emergency night visits and a lack
of understanding in society. Therefore, establishment of
a system for true total care with early long-term vision
and social consciousness is strongly desired. Asthma
mortality is a serious problem that requires the estab-
lishment of a large, long-term project in order to
investigate the cause of the relatively high mortality rate
among asthma patients in Japan and to propose mea-
sures against this.
Key words: adolescence, asthma death, bronchial
asthma, epidemiology, infantile asthma, young adult.
INTRODUCTION
The prevalence of allergic diseases, including bronchial
asthma, has been increasing worldwide. Taking into
account the recent increase in the mortality due to
bronchial asthma among the young population in Japan,
analysis of the disease and the development of measures
against the mortality are urgently required. In addition,
the increased hospitalization rate for infant asthmatics
and the lack of an appropriate treatment regimen for this
group of patients are dawning as other problems requir-
ing investigation.
Based on data from an analysis of the present status of
infant asthmatics, trends and characteristics of clinical
symptoms in adolescent through to young adult patients,
long-term prognosis in pediatric patients with severe
asthma who have been hospitalized for long periods, the
pulmonary functional perspective in young patients with
severe bronchial asthma and mortality in young asthma
patients, including my own views on Global Initiative for
Asthma (GINA) guidelines1 and the Japanese guidelines
for the treatment of asthma in adult patients (JGL ’98),2
the following paper discusses the treatment and manage-
ment of patients with severe asthma, ranging from infants
through to young adults.
THE SHIFT IN THE NUMBER OF PEDIATRIC
ASTHMA PATIENTS AND AGE-SPECIFIC
DISTRIBUTION
Looking at the number of pediatric asthma patients in
National Minami Fukuoka Chest Hospital, the number of
out-patients subsequent to 1984 has been between 2000
and 2500 annually. The number of patients hospitalized
due to asthma attacks, which once amounted to 1280, has
started to decrease in recent years. There are two peaks for
hospitalization rates: one in the adolescent population 
and one in the infant population. The figures show that of
the 16 791 asthma patients who were hospitalized and
received treatment during the 24 years between 1974 and
1997, there were 1.34-fold more boys than girls (Fig. 1).
Dividing these 24 years into three 8 year periods
(1974–1981, 1982–1989, and 1990–1997), we can
see a significant increase in the number of younger
patients hospitalized in the most recent 8 year period,
whereas a significant decrease is observed in the number
of school children hospitalized (Fig. 2).
A particular characteristic in this shift of the incidence
of hospitalization is observed: the incidence of hospital-
ization of younger patients because of asthma attacks
has not decreased but, rather, has shown an increase 
in terms of absolute values. This increase in hospitaliza-
tion is characterized by a high complication rate with
respiratory tract infections, such as upper respiratory tract
infection, bronchitis and pneumonia. The rate of compli-
cations with infections was higher and more significant in
infants (Fig. 3).
The number of young adult patients with asthma has
been increasing; however, this may be a matter of the
clinical course of asthma. Because patients with mild,
moderately severe or severe asthma may improve as they
become older, if we work in the same pediatrics office for
a long time, we would be able to see a greater number 
of patients with severe asthma to a certain extent; that 
is to say, we would naturally end up seeing a greater
number of older patients in the pediatrics department. 
We conducted two epidemiological surveillances on
approximately 50 000 elementary school children in 11
prefectures of western Japan between 1982 and 1992. In
these studies, the prevalence rate for asthma had been
decreasing gradually in both boys and girls in the 1st
through to the 6th grades in the past, whereas in 1992,
the rate of decrease had slowed down and the prevalence
rates, at the end of the surveillance, had even been higher
for all grades (Fig. 4).3 Data from other regions in
Japan4–9 also showed the same pattern as our data. This
may be one of the reasons for the greater number of older
patients with bronchial asthma observed in pediatrics.
In our recent surveillance of elementary school chil-
dren using the American Thoracic Society–Division of
Lung Diseases (ATS-DLD) questionnaire (Japanese
version/revision), the results indicated a prevalence rate
of asthma of approximately 5% in almost every region.10
In a study conducted by the International Study of
Asthma and Allergies in Childhood (ISAAC) group, the
results showed a worldwide increase in the prevalence of
allergies and asthma.11 In Japan, the ISAAC study was
conducted in Fukuoka City. The 12 month prevalence of
asthma symptoms among 1st graders and junior high
school 2nd graders was 17 and 13%, respectively. Japan
has the highest prevalence rate of asthma symptoms in
children in all south-east Asia (Fig. 5).11
The ISAAC study used a rough definition of the
disease. Therefore, some patients who did not have
bronchial asthma may have been included in this
‘wheeze’ group.
In contrast, despite epidemiologic data that showed no
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Fig. 1 Annual changes in acute hospitalizations for asthma from 1974 to 1997, Division of Pediatrics, National Minami Fukuoka
Chest Hospital. ( ), females (n = 7163); (), males (n = 9628).
variation in the age-specific incidence rate for asthma
symptoms, the age-specific rates for recipients of asthma
treatment showed a different pattern. The number of
recipients of asthma treatment gradually decreased in the
1–4-, 5–9-, 0- and 10–14-year-old age groups, while
the number of recipients of asthma treatment in the 15
years or older age group showed a rapid decrease. This
may be one of the outstanding problems in the treatment
and management of young adult patients with severe
bronchial asthma, as I will now discuss.
DIFFERENCES IN ASTHMA TREATMENT BETWEEN
PEDIATRIC AND INTERNAL MEDICINE UNITS
A study was conducted on the patient distribution in the
pediatric and internal medicine units of three major
hospitals in Japan (National Minami Fukuoka Chest
Hospital, National Sagamihara Hospital and Doai
Memorial Hospital).12 The results were as follows: a
greater percentage of patients aged between 15 and 
19 years had visited the pediatric unit (62.4%) and a
greater percentage of patients aged between 20 and 24
years had been shifted to the internal medicine unit
(30.0% of these patients had visited the pediatric unit),
whereas most patients over 30 years of age had visited
the internal medicine unit. This makes the problem of
treatment more complicated in young adult asthmatics.
These three institutions, together with some other insti-
tutions (Kinki Medical School, Tamana Chuo Hospital,
National Children’s Hospital and Kyushu University),
have organized the Adolescent Asthma Research Group.
This group has conducted a study on a total of 170
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Fig. 2 Annual changes in age distribution of patients hospitalized for asthma from 1974 to 1997, Division of Pediatrics, National
Minami Fukuoka Chest Hospital. (), 1974–81 (n = 2828); ( ), 1982–89 (n = 7513); (), 1990–97 (n = 6450).
patients, consisting of 69 male patients and 101 female
patients aged 12–22 years. Ideally, the severity of asthma
should be equal when the adolescent patient is assessed
by the internal medicine and pediatric severity standard
classification systems. However, the equality rate in this
study was 73%.13 In some cases in which the severity of
the disease was assessed differently between the pediatric
and internal medicine units, it was found that internists
tended to judge the severity of the patients’ asthma milder
than pediatricians. This is to say that up to one-quarter of
all patients had been judged differently, being considered
as having severe asthma by a pediatrician but moderately
severe asthma by an internist, or moderately severe
asthma by a pediatrician but mild asthma by an internist.
This is the group of patients who may encounter serious
problems when they are transfered from pediatric care to
internal medicine care.
The therapeutic score is an important issue when con-
sidering whether an internal medicine classification or a
pediatric classification should be used to determine the
severity of asthma in adolescent patients. The Japanese
Society of Pediatric Allergy and Clinical Immunology
(JSPACI) has recently made a proposal regarding ther-
apeutic scores.2 When the internal medicine severity
classification was used in adolescent/young adult pa-
tients, the therapeutic score did not necessarily work as
well as the classification, whereas patients more severe
asthma were given higher therapeutic scores when the
pediatric severity classification was used. However, there
remains a further question of when the internal medicine
severity classification should start to be used, with no con-
clusions provided from the Adolescent Asthma Research
Group study.
We questioned all directors of JSPACI as to what drug
therapy should be administered to patients with Step 2:
Mild Persistent and Step 3: Moderate Persistent Asthma in
the guidelines. Compared with adult patients, the differ-
ence was apparent in pediatric patients with Step 2
asthma, to whom no steroid inhalation is administered
but high-dose disodium cromoglycate (DSCG) inhalation
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Fig. 3 Age distribution of
acutely hospitalized asthmatics
in (a) 1977, (b) 1987 and 
(c) 1997, Division of Pediatrics,
National Minami Fukuoka 
Chest Hospital, with () or with-
out ( ) concomitant infection.
is used instead. Steroid inhalation was not frequently
used in patients with mild Step 3 asthma either. No
steroids were administered orally to children with Step 3
asthma. In particular, this suggests that steroid use is 
the outstanding issue in terms of differences between
pediatric treatment of asthma and internal medicine
treatment of asthma.
PROBLEMS RELATED TO SCHOOLWORK AND
SOCIAL WORK
For adolescents through to young adult patients with
asthma, their schoolwork is another underlying problem in
terms of the substantial social/psychological problems
resulting from their condition. Asthmatic children with
uncotrollable severe asthma often receive institutionalized
therapy in Japan. The average school absence rate in
institutionalized patients 20 years ago was approximately
15%. Nevertheless, a recent study reported a school
absence rate of over 25%.14 This is a serious problem
because, with regard to the school absence rate and
school records for elementary and junior high school-age
out-patients, the more severe the disease, the higher the
absence rate; this results in a poorer school record, which
is more significant for patients at the junior high school
level than for patients of elementary school age. As a
result, a greater number of underachievers, who cannot
achieve their potential level at school based on their
intelligence and achievement deviations, is found at
higher grades.
In addition, in a survey of long-term prognosis of insti-
tutionalized patients with severe asthma, various
psychosocial problems were identified.13 These include
problems in gaining higher education, getting a job and
daily life; patients who remain symptomatic have a ten-
dency to face more serious problems. A considerable
254 S NISHIMA
Fig. 4 Prevalence rate of bronchial asthma of schoolchildren in western Japan in 1982 (n = 55 388) and 1992 (n = 46 718).
(), males in 1992 (n = 23 574); (), females in 1992 (n = 23 144); (), males in 1982 (n = 28 035); (), females in 1982 
(n = 27 353).
number of young adult patients continue to consulting
with physicians and receive medical therapy.
PECULIARITY OF CLINICAL SYMPTOMS IN
ADOLESCENT/YOUNG ADULT PATIENTS
The clinical symptoms in young adult asthma patients
differ from those in younger children, middle-aged and
older patients. As pointed out already, there are differ-
ences in the age distribution of patients hospitalized 
due to asthma attacks; there was a peak in the younger
childhood population and another in the adolescent
population. Cases complicated with respiratory infections
were concentrated in the infant population. This suggests
that fewer adolescent patients with severe asthma attacks
have worsened due to complications with respiratory
infection (Fig. 3).
Atelectasis in asthma patients, particularly that of the
middle lobe, is common and occurs overwhelmingly in
younger children, whereas only a few cases of atelectasis
are found in older children with asthma. In contrast,
mediastinal emphysema and subcutaneous emphysema,
called air leak syndrome, are concentrated in the young
adult population.15
LONG-TERM PROGNOSIS OF PATIENTS WITH
SEVERE CHILDHOOD ASTHMA WHO HAVE
HAD LONG-TERM HOSPITALIZATION
(INSTITUTIONALIZED THERAPY)
We conducted the fourth surveillance by questionnaires
and interviews in 1996 to examine the long-term progno-
sis of patients with severe bronchial asthma who have
had long-term hospitalization (institutionalized therapy).
Subjects comprised a total of 127 patients with bron-
chial asthma who had been admitted and discharged
from the National Minami Fukuoka Chest Hospital
during the 4.5 years subsequent to 1974. The average
age of asthma onset was 2.6 years and the age on
admission was 8.5 years. A total of four surveys were
performed from 1980 through to 1996.13
In the data submitted in 1996, a total of 48 patients
were aged between 24 and 35 years, with a mean age of
29.5 ± 2.8 years. The remission rates in the past studies
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Fig. 5 12 month prevalences of self-reported asthma symptoms from written questionnaires (13–14-year-olds; from ISAAC4).
were 15.7–40.9%; however, the rate among the 48
patients of the 1996 study was 27.2%, which is relatively
low for a long-term observation (Table 1). In our study, the
important result was a mortality rate of 12.7%, approxi-
mately 40-fold higher than that of asthma patients in this
age group in Japan. In the recent yearly asthma status,
there were some patients who had never had attacks,
whereas a great number of patients remained sympto-
matic and many were treated with steroid inhalation.
Looking at the hospital visits status, 64.6% of patients
were still consulting with physicians; half at the internal
medicine unit and the other half at the pediatrics unit.
Results of pulmonary function measurements were as
follows: percentage forced vital capacity (%FVC) 102.2 ±
15.9%; percentage forced expiratory volume (%FEV1.0) in
1 s 84.8 ± 17.2%; percentage peak expiratory flow
(%PEF) 80.6 ± 26.3%; and percentage V˙50 50.3 ±
25.5%. A greater decrease in %PEF in young adult sub-
jects who have had long-term hospitalization compared
with patients with childhood severe asthma was noted
(Fig. 6). Some patients were well controlled, while a con-
siderable number of patients continued to have low
pulmonary function values. We compared serum IgE
levels in patients at a mean age of 9 years on discharge
and 20 years later. The mean IgE value at age 9.1 years
was 2022.5 ± 1362.5 IU/mL, whereas the value
dropped to 529.4 ± 445.9 IU/mL at 28.4 years, with
only one patient of 16 cases showing an elevated value
of serum IgE. The total IgE values decreased to nearly to
one-quarter of the level 20 years ago.
When we investigated elementary school children and
compared the IgE value distribution in these children with
a healthy population, asthma patients and wheezy chil-
dren were characterized by a large peak distribution at
1000–2000 IU/mL and only a small peak at 500–1000
IU/mL.16 The IgE value, in general, decreased after the
age of 20 years. To understand this, we considered that
this pattern may be attributable to differences in house
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Table 1 Prognosis of severe intractable asthmatic children in National Minami Fukuoka Chest Hospital
Survey n (response Age Prognosis (%)
rate, %) (years) Remission Improved No change Worsened Death
1980 115 (90.6) 13 15.7 57.3 14.8 2.6 2.6
1984 109 (85.8) 17 33.0 50.5 11.0 2.7 2.8
1990 93 (73.2) 22 40.9 45.2 5.4 3.2 5.4
1996 48 (37.8) 29 27.2 52.7 3.6 3.6 12.7
In 1980 and 1984, patients were studied 3 years after institutionalized therapy; in 1990, patients were studied 15 years after institutionalized
therapy; in 1996, patients were studied 22 years after institutionalized therapy.
Fig. 6 Current pulmonary
function in cases requiring insti-
tutional therapy (long-term
hospitalization). Patients were
discharged from hospital at a
mean age of 9.6 years and pul-
monary functions tests were
performed on patients with a
mean age of 28.7 years. FVC,
forced vital capacity; FEV1.0,
forced expiratory volume in 1 s;
PEF, peak expiratory flow.
dust mite environments between the past and present
rather than individually reduced values. However, in the
results of the long-term follow-up study,13 an early indi-
vidual total IgE decrease has been suggested, which may
reflect a decrease in IgE-medicated immunity/allergic
reactions in individuals.
I will now discuss the part played by menstruation,
pregnancy and birth. Our data13 did not show any effect
of menarche on asthma status: unchanged 70.6% at 
the time, improved 23.5% and growing worse 5.9%.
Because the mean age of the female subjects was 26
years, menstrual asthma may be detected, yet the rate of
menstrual asthma was rather low at 23.5%, 60% of which
consisted of premenstrual asthma patients.
Regarding asthma in pregnancy, Gilbert17 has reported
that one-third of patients will improve, one-third will
remain unchanged and one-third will become worse. The
data of our study13 have indicated that 66.7% of asthma
patients improved due to pregnancy and one-third of
these have been doing well during the postnatal period;
no aggravated case due to pregnancy has been reported
in 17 subjects.
Whether asthma is a handicap for marriage and what
will happen in the future are questions that we often hear
from patients and their parents. Fortunately, in the group
of patients who were concerned about asthma before
marriage, only one case (3.4%) was reported to have
negative consequences, preventing people from getting
married. Twenty-six babies have been born to married
patients and for this group of babies the prevalence rate
of allergic diseases was found to be 34.6%, while the
prevalence rate of asthma was 15.4%. Data from epi-
demiologic surveillance in the western regions of Japan
indicate that the rate of asthma patients in families with a
history of asthma was 9% in 1982 and 12% in 1992;3
therefore, the rates for subjects in our survey were a little
higher. However, the study in the western Japan was con-
ducted on elementary school children, whereas a great
number of preschool children have been involved in our
study. Therefore, the asthma prevalence rate among off-
spring of patients with severe asthma may be higher than
in out-patients with asthma.
PULMONARY FUNCTION OF YOUNG ADULT
PATIENTS WITH SEVERE BRONCHIAL ASTHMA
As discussed previously, the pulmonary function of patients
who had experienced long-term hospitalization therapy 
20 years ago were, unfortunately, not good (Fig. 6).
Measurements of FVC were normal, %PEF and %FEV1.0
were rather lower and V˙50 was apparently equivalent to
that of patients with severe asthma. Among the elemen-
tary school children classified into four groups as children
with no asthma, children with mild asthma, children with
moderately severe asthma and children with severe
asthma, all subjects showed greater than 100% in %PEF,
90% in %FEV1.0, which was somewhat lower, and a group
of severe asthma patients showed 50% in %V˙50 (Fig. 7).
The subjects in this study showed values nearly equivalent
to those of children with severe asthma except for %PEF
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Fig. 7 Mean (±SD) pulmonary function in normal (A; n = 49) and asthmatic (B, mild persistent asthma, n = 50; C, moderate
persistent asthma, n = 51; D, severe persistent asthma, n = 38) children. (a) Forced vital capacity (FVC), (b) forced expiratory
volume in 1 s (FEV1.0), (c) peak expiratory flow (PEF) and (d) V˙50.*P < 0.05, †P < 0.01, ‡P < 0.001.
values, which were lower. Namely, the low %PEF values in
young adult patients were apparently different from those
of severe asthma patients at elementary school age.
We performed pulmonary function tests after the
administration of epirenamine hydrochloride, subcuta-
neous injection, to four groups of patients: a group of
patients who have been doing well after hospitalization
through to a group of patients who were receiving med-
ication but still experiencing attacks. The results observed
for V˙50 showed that some patients who were not doing
well had an initial percentage value less than 50% and
that even patients who were doing fairly well had values
as low as 60%. The incidence of patients whose pul-
monary function values were elevated to greater than
80% of predicted values after the administration of the
bronchodialator were low for V˙50 overall and this was sig-
nificant in patients who were not doing well. We have
experienced few cases of patients’ ventilatory function in
small airway parameters recovering to 100% after admin-
stration of bronchodialator. To my understanding, before
20 years of age, airway constriction may persist continu-
ously in patients with severe asthma, even when the
patients are in a good stable condition; this is supported
by the recent chronic airway inflammation theory.18,19
We compared three groups of patients, namely a
group of patients who had died of asthma, a group of
patients with episodes of severe attacks and a group with
mild asthma, aged 13–15 years with the same back-
ground. The data indicated that, compared with mild
cases, the group of patients who died of asthma had
apparently lower V˙50 values.20 There was no difference
between the severe-type group and those patients who
died of asthma and this could be a serious problem
because it means that we are not able to distinguish the
group at risk of death from other groups by pulmonary
function values before the asthma attack that leads to
their death. The results of pulmonary function tests of
patients at a mean age of 30 years, who were questioned
in the follow-up study, were nearly equivalent to those of
patients who had died of asthma. These patients were
therefore considered as a high-risk group and will require
adequate treatment and regular management.
Patients with severe asthma can easily develop airway
constriction (i.e. exercise-induced asthma (EIA) or exercise-
induced bronchospasm (EIB)).21,22 Patients with mild,
moderately severe and severe asthma are clearly more
apt to develop EIB than healthy children (Fig. 8).22 The
airways of these patients are extremely sensitive and this
becomes an impediment in their activity of daily living
(ADL) and quality of life (QOL). As a result, junior high
school students with severe asthma are inferior to the
national average in terms of back muscle strength,
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Fig. 8 Maximal percentage fall in (a) forced vital capacity (FVC), (b) peak expiratory flow (PEF) and (c) V˙50 in asthmatic children 
(A, normal; B, mild asthma; C, moderate asthma; D, severe asthma) by bicycle ergometer.22 *P < 0.01, †P < 0.005.
repeating sideway jumps and grip strength, and their
physical performance is not comparable. We are unable
to recommend vigorous exercise to severe asthma
patients with a high EIB tendency without premedication.
At our hospital, we have been performing swimming
training, which is less likely to cause EIB, all year round in
order to strengthen these patients physically as well as to
improve their bronchial hypersensitivity.
ASTHMA MORTALITY
Incidents of mortality from asthma for the entire
Japanese population have been decreasing gradually
over the past 10 years to approximately 5.0 cases per
100 000. In the past, sudden deaths of boys aged
10–14 years became a worldwide issue from 1965
through the 1970s, and it still remains vividly in our
memory. These sudden deaths were first reported in
England and Wales9 and the mortality rate among boys
aged 10–14 years in Japan was elevated to sevenfold.24
However, this rate has decreased to 0.4–0.5 in the 
5 years subsequent to 1970. Asthma mortality has been
said to be increasing recently, but cases of this in the
population aged 10–14 years, which became an inter-
national issue in 1970, has not increased in Japan 
(Fig. 9). However, mortality in the population group
ranging from 15 to 29 years took an apparently different
course. In 1980, mortality in both males and females in
this age group had started to increase and then contin-
ued increasing to threefold the previous rate in the
subsequent 10 years. In the population older than 
30 years, asthma mortality showed only a little increase.
The recent increase in asthma mortality in the 15–29-
year-old age group was peculiar. However, the mortality
rate in this age group has been decreasing since
1995.25
We have unfortunately experienced death in 26
asthma patients during the past 26 years among the
patients registered at the Pediatric Unit of National
Minami Fukuoka Chest Hospital. The most recent death
occurred in June 1996. Two patients died from malignant
tumors, two patients experienced sudden death due to
unknown causes and other patients died of asthma. We
have analyzed a total of 24 patients, including these two
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Fig. 9 Asthma mortality in three age groups (, 5–34 years; , 10–14 years; , 15–29 years) in Japan from 1960 to 1999.
sudden-death patients because they had severe asthma.
The age distribution in the 24 patients who died ranged
from 3 to 29 years, with a mean age of 15.5 ±
7.4 years. Fourteen cases were males. There was an
apparent difference in the age distribution between
cases of death from asthma and patients with near-fatal
asthma (NFA) in the Minami Fukuoka Chest Hospital.
Although a greater number of NFA patients were distrib-
uted in the younger age group, the mortality in this age
group was low and showed a similar tendency to the
national data published by Japanese Society of Pediatric
Allergy Asthma Mortality Committee.25 The data of our
hospital indicated a greater number of NFA attacks in
young children. A significant difference was observed in
the 22 severe patients, accounting for 92% of a total of
24 of patients, whereas in the data of the Asthma
Mortality Committee, the rate of severe asthma patients
was as low as 32.6%. Patients with severe asthma in NFA
cases have amounted to 65.5% in Minami Fukuoka
Hospital as well, whereas the national surveillance rate
was 35.4%. In addition, there was an important differ-
ence in the place of death between our 24 patients and
those of the national surveillance. In most of our cases,
patients had already died on their way to hospital. As a
result, death from asthma in pediatric patients in our
hospital were characterized by death from asthma
attacks in young adult patients outside the hospital.
Another characteristic was that the mean age of the most
recent 13 patient deaths was 19.6 years, showing a shift
to a group of older patients. These marked differences
between data in our hospital and those of the national
surveillance are a problem that needs to be solved in
order to investigate the cause of asthma mortality and to
plan an appropriate management regimen.
Examining the risk factors for asthma mortality and
NFA, delayed visits to hospitals and an overreliance on 
β-adrenergic receptor agonists metered dose inhaler
(MDI)/nebulizer have been indicated as contributing
factors. Among 10 cases of death in our patients in
whom the use of β-adrenergic receptor agonists could be
traced, 70% may have been overreliant, which is higher
compared with cases of NFA. Among the β-adrenergic
receptor agonists in use, there is some concern about
the use of fenoterol;26 there are some points that 
should be noted with regard to the use of β-adrenergic
receptor agonists MDI in Japan. To look at the number 
of β-adrenergic receptor agonist MDI canisters sold
yearly from 1985 to 1995, almost the same amount of
fenoterol, procaterol and salbutamol has been sold,
whereas the amount of isoproterenol MDI sold
decreased slightly in 1995, even though the frequent
occurence of asthma mortality in 1965–1970 was con-
sidered to be associated with the use of isoproterenol
MDI. The reason for this may be that once a patient
starts to use a specific vigorous β-adrenergic receptor
agonist MDI, it cannot be easily changed to another
medication. Among our out-patients, a considerable num-
ber of patients may certainly resist our efforts to change
their medication. Although there are various guidelines
for asthma treatment, the actual β2-adrenergic receptor
agonist MDI usage status in Japan seems to be working
unrelated to the cautions indicated in the recent guide-
lines before 1998.
The well-known data from New Zealand are contrary 
to expectations.27 The data from the Japanese Society 
of Pediatric Allergy Asthma Mortality Committee showed
nearly the same results as the New Zealand studies and the
Saskatchwan study.32 However, because the Japanese data
were not constant in terms of background factors and were
of an in sufficient level in terms of evidence-based medicine
(EBM), we are unable to come to any conclusions (Table 2).
The reasons for mortality concentrated around adoles-
cents through to young adults may be because of the
following.
1. The shift of initiative for the treatment from a physi-
cian or family members to the patient himself/herself
results in a disturbance in appropriate therapy.
2. Daytime hospital visits on an out-patient basis may
become difficult due to increased schoolwork or work-
load, resulting in fewer, intermittent visits.
3. The pathophysiology may be altered by more
frequent air leak syndrome complications or menstrual
influences.
4. It may be hard for a patient to adapt to either
internal medicine or pediatrics either physically or
psychologically.
5. Starting to live alone makes it difficult to get support
from others.
Particularly regarding the fifth point, male patients are
more likely to be isolated without any support, which may
become a big problem. The asthma management guide-
lines for adolescents through to young adult patients with
intractable asthma should be set separately. To set up
separate guidelines, important points to consider include
how to judge the severity of the asthma, adjustments 
in the understanding of medical staff and family of 
the patients, compliance, education of school/workplace
and identification of high-risk patients.
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CONSIDERATIONS IN GINA
I am going to point out some points for consideration in
the asthma management program GINA.
The six-part asthma management program consists of
the following. 
1. Educating patients to develop a partnership in
asthma management.
2. Assessing and monitoring asthma severity with
symptom and lung function measurements.
3. Avoiding or controlling asthma triggers.
4. Establishing medication plans for long-term man-
agement.
5. Establishing plans for managing exacerbations.
6. Providing regular follow-up care.
With regard to the second point, monitoring asthma
severity, asthma attacks are classified into mild, moderate
and severe, drawing lines at 80 and 60% in terms of
%PEF values and at 45 mmHg in PaCO 2. However, 
the question is whether this could actually be applied 
to childhood asthma patients or not. According to data
from our study examining changes in patients admitted
from asthma attacks subsequent to β-adrenergic receptor
agonist inhalation, the %PEF values of admitted patients
may be as low as 30% and, even after the β-adrenergic
receptor agonist inhalation, these values increase to
approximately 40%. However, patients may be dis-
charged with values of 60–80% after β-adrenergic
receptor agonist inhalation. Therefore, if we follow and
apply the GINA guidelines, which indicate we should
admit patients with %PEF values of 60% or less after 
β-adrenergic receptor agonist inhalation, a considerable
number of patients would have to be admitted (Fig. 10).
Similarly, another question is whether or not 45 mmHg
PaCO 2 could be correctly applied to children. The six
condition-specific PaCO 2 values are measured when
asthma is under control, rhonchi with auscultation, mild
attack, moderate attacks, severe attacks and severe attacks
with disturbance of consciousness. We can find that even
patients who are under a severe attack never have a value
greater than 45 mmHg on average and when the value is
greater than 45 mmHg the patient may be in a very serious
condition with agitation or disturbance of consciousness
(Fig. 11).33 Therefore, the standard value of 45 mmHg is
very risky it is to be applied to preteen or younger patients
and should be lowered to 40 mmHg.
Another consideration is about point 3, ‘Environmental
control measures’ in the asthma management program
of GINA. Sporik et al.34 have suggested that infants who
are exposed to house dust mite at birth have a greater
chance of developing allergies. There is no doubt that
patient education about their environment is important.
In fact, we have been giving instructions, such as using
air-conditioning systems, caution regarding bed clothes,
methods of house cleaning, wider storage space and not
keeping animals indoors. However, it is difficult for many
patients to follow all these instructions and I will show
how difficult it is using cats as an example. According to
the data of the Petfoods Industry Association (T Ooki,
Secretary General Petfoods Industry Association, pers.
comm., 1995), 10.6% of Japanese households now
have cats; 8.0% are estimated to keep cats in the house.
However, data on our pediatric out-patients indicate that
a considerable number of older asthma patients often
keep cats and as high as 64.7% of patients who have cats
(n = 51) were sensitized, whereas 21.2% of patients who
did not have cats were sensitized. Even though we give
instructions to not keep cats, a significant number of
patients, in fact, still keep cats. Considering an ideal envi-
ronment, some lifestyle changes are required and, in
addition, great deal of energy is required, either econom-
ically or timewise, which makes it difficult to follow the
instructions. Thus, we cannot help but rely only on medi-
cations. Without any insurance coverage, a 3 day period
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Table 2 Proportion of cases (asthma deaths) and controls prescribed fenoterol in studies in New Zealand, Saskatchewan and
Japan
Total % of cases % of controls OR 95% CI
deaths on fenoterol on fenoterol
First New Zealand study29 117 51.3 40.4 1.6 1.0–2.3
Second New Zealand study29 58 51.7 35.7 1.9 1.1–3.4
Third New Zealand study30 112 59.8 45.9 1.8 1.2–2.7
Saskatschewan study31 44 47.7 15.9 4.8 2.5–9.3
Japanese study28 30 53.4 18.3* 5.1 2.6–9.9
*Market share; this study did not include a formal control group.
OR, odds ratio; CI, confidence interval.
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Fig. 10 Changes in pulmonary function before and after isoproterenol inhalation on admission () and at discharge (). Data
are the mean±SEM. FVC, forced vital capacity; FEV1.0, forced expiratory volume in 1 s; PEF, peak expiratory flow; MMF, maximal
mid-expiratory flow.
Fig. 11 Arterial blood gases in asthmatic children.33 0, no rhonchi of auscultation; 1, rhonchi only; 2, mild attack; 3, moderate
attack; 4, severe attack; 5, respiratory failure with disturbance of consiousness. *P < 0.005.
hospitalization of asthma patients may cost up to
US$700–800, which may be an economic burden on fre-
quently hospitalized patients, making it harder to improve
the life environment; thus, the vicious cycle develops.
The GINA defines controlled asthma as: (i) minimal
(ideally no) chronic symptoms; (ii) minimal (infrequent)
exacerbations; (iii) minimal (ideally no) need for pro re
nata (p.r.n.; as needed) β2-adrenergic receptor agonist;
(iv) no limitations on activities; (v) (near) normal PEF and
PEF circadian variation of less than 20%; (vi) minimal (or
no) adverse effects from medicine; and (vii) physical and
psychological status are kept normal. The questions are,
for example, whether it is possible to keep PEF circadian
variation less than 20% or whether it is appropriate for
the standard to be applied to children that asthma sever-
ity is assessed as paroxysmal with over 80% %PEF,
chronic–severe with less than 60% and mild with a circa-
dian variation of less than 20%. As previously discussed,
%PEF values in children, even in severe-type asthma
patients, could be averaged over 100%. In our study, in
the group of patients with a mean age of 30 years, 80%
of PEF measurements were obtained when no attacks
were observed. Therefore, the value of 80% in the GINA
guidelines is not appropriate, at least for patients younger
than adolescents, and cannot be applied to childhood
asthma patients. Pulmonary function measurements in
some childhood patients may show dynamic changes
and it is very difficult to keep PEF circadian variation of
less than 20% in patients with severe asthma, even when
the patient’s asthma appears to be well controlled.
As I have mentioned, although various ideals are indi-
cated in the treatment and management guidelines of
GINA, we must, unfortunately, face many underlying
problems when we try to apply these guidelines uniformly,
especially to young adult patients who often have
complex backgrounds.
CONCLUSIONS
Overall, the control of childhood bronchial asthma could
certainly be more easily achieved now. However, patients
with severe intractable asthma remain problematic.
These patients face many problems, such as long-term
use of multiple medications, disturbances in QOL, obsta-
cles in higher education/work, an inadequate system of
emergency night visits and a lack of understanding in
society. The establishment of a system for true total care
with early long-term vision and social consciousness is
strongly desired.
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